GlassScriptPhysician profile
Christopher B Wills
NPI 1558622506
$3,539.96
in general payments reported to CMS, 2019-2025
26 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.03 · 2020: $114 · 2021: $548 · 2022: $884 · 2023: $1,076 · 2024: $726 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.21 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $468.16 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $453.55 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $387.79 | 2019-2024 | |
| Lilly USA, LLC | $360.65 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $252.34 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.33 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Exact Sciences Corporation | $127.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $103.06 | 2022-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.82 | 2021-2023 | Xifaxan |
| Ibsa Pharma INC. | $77.41 | 2021-2023 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $67.61 | 2020-2024 | Arexvy, Shingrix |
| Aimmune Therapeutics, INC. | $67.37 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $42.87 | 2022-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Myriad Women'S Health, INC. | $36.66 | 2023 | Myrisk |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $33.82 | 2024 | Omnipod |
| Nestle Healthcare Nutrition INC. | $29.42 | 2023 | |
| Idorsia Pharmaceuticals US INC | $27.71 | 2022-2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $26.58 | 2021-2022 | |
| Becton, Dickinson and Company | $26.54 | 2025 | Site-Rite |
| Amgen INC. | $24.92 | 2024 | Repatha, Otezla |
| Dynavax Technologies Corporation | $23.87 | 2024 | Heplisav-B |
| Astellas Pharma US INC | $20.42 | 2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $16.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.78 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.